Genome Editing– tag –
-
CRISPR’s Clinical Horizon: Liv Hospital Report Maps 2026 FDA Landscape and Broad Therapeutic Potential
Liv Hospital Turkey Overview Liv Hospital has published a comprehensive review outlining the latest advancements in CRISPR gene-editing technology, emphasizing its revolutionary impact on medical treatments. The report highlights breakth... -
NIH-Funded Team Discovers Miniaturized Al3Cas12f CRISPR Enzyme, Dramatically Enhancing In Vivo Precision Delivery and Solving a Major Gene Therapy Bottleneck
National Institutes of Health (NIH) (News Release) USA Overview An NIH-funded research team has discovered an improved CRISPR gene-editing system enabling precise in vivo gene delivery. This breakthrough involves identifying the naturall... -
Intellia Therapeutics Advances CRISPR Gene Editing: Lonvo-z Achieves Phase 3 Success for HAE, Targeting Mid-2027 U.S. Launch; Nex-z Phase 3 Enrollment Resumes for ATTR
Intellia Therapeutics, Inc. (Press Release) USA Overview Intellia Therapeutics reported positive Phase 3 results for lonvo-z in hereditary angioedema (HAE), with a Biologics License Application (BLA) submission to the FDA planned for H2 ... -
FDA Approves Tregzi, First Regulatory T-Cell (Treg) Immunotherapy for Chronic GVHD Prevention, Expands Casgevy Indication to Pediatric Patients
Cell and Gene Therapy Catapult USA Overview On June 30, 2026, the U.S. FDA approved Tregzi, the first regulatory T-cell (Treg)-based immunotherapy designed to prevent chronic graft-versus-host disease (GVHD) and improve survival. Tregzi ... -
Intellia Therapeutics Reports Positive Phase 3 HAELO Data for lonvo-z in HAE and Resumes Nex-z ATTR Phase 3 Enrollment
Intellia Therapeutics USA Overview Intellia Therapeutics announced positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema (HAE), published in the New England Journal of Medicine. The company anticipates FDA Biologics L... -
Editas Medicine’s CRISPR Candidate EDIT-401 Achieves Over 90% Reduction in LDL Cholesterol in Non-Human Primates, Suggesting Long-Term Durability for Dyslipidemia
Editas Medicine USA Overview Editas Medicine announced updated preclinical data for EDIT-401, a CRISPR-based investigational drug for dyslipidemia, showing highly promising results. A single dose of EDIT-401 in non-human primate models a... -
CRISPR Gene Editing Therapies Limited to Ex Vivo Approvals for Sickle Cell and Beta-Thalassemia in 2026; In Vivo Candidates Show 87% Attack Reduction and 62% Cholesterol Decrease
DeepDNA USA Overview As of August 2026, the only globally approved CRISPR gene-editing therapies are ex vivo treatments for sickle cell disease and transfusion-dependent beta-thalassemia. However, in vivo therapies are demonstrating sign... -
Washington University Reports Promising Early Results for Aggressive Blood Cancers with Combined CRISPR Gene Editing and Stem Cell Transplant
The Brighter Side of News USA Overview Researchers at Washington University School of Medicine in St. Louis reported promising early results from a clinical trial combining CRISPR gene editing with stem cell transplantation to treat aggr... -
Vertex’s CASGEVY Gene Therapy Expands FDA Approval to Pediatric Patients 2+ for Sickle Cell and Beta-Thalassemia; Umoja’s In Vivo CAR-T for Solid Tumors Enters Clinic
BioInsights USA Overview July 2026 marked significant progress in gene and cell therapy access, with Vertex Pharmaceuticals' CASGEVY receiving expanded FDA approval for pediatric patients aged 2 and older with sickle cell disease and tra... -
BioCentury Analyzes Commercialization Strategies for Gene-Edited Hematopoietic Stem Cell Therapies, Discussing Solutions for High Costs and Manufacturing Complexity
BioCentury USA Overview BioCentury published an analytical article focusing on commercialization strategies for companies developing gene-edited hematopoietic stem cell (HSC) therapies. The article discusses high treatment costs, manufac...
